Kornimate/medical-research-clean huggingface dataset:
use of export in primary percutaneous coronary intervention

Conditions: ST-segment Elevation Myocardial Infarction (STEMI); Total Occlusion of Coronary Artery; Primary Percutaneous Coronary Intervention

Summary: aim of this single center randomized open label trial with blinded in-hospital outcomes assessment is designed with aim to compare manual thrombus aspiration followed by percutaneous coronary intervention (pci) strategy with pci alone.

clinical benefit of manual aspiration has been a contentious point of debate and it is class iii indication in current clinical practice guidelines, however, recent observational data by kumar d et al. showed benefits of usage of export in terms of favorable in-hospital outcomes and lesser complication rate in patients with total occlusion, furthermore, benefits of usage of export was observed to be directly associated with duration of chest pain at the time of thrombus aspiration. however, these observations are limited to immediate and in-hospital outcomes and data regarding efficacy of manual thrombus aspiration are not available. hence this single center randomized open label trial is designed with specific aim to test the following hypothesis for stemi patients with total occlusion undergoing primary pci; * whether use of export catheter reduces in-hospital and short term adverse events * whether use of export reduces slow flow or no reflow * whether use of export reduces the use of intracoronary drugs * whether use of export within 6 hours of symptom onset significantly reduces in-hospital and short term adverse events consecutively recruited patients will be randomized to either primary pci with export or primary pci alone group in 2:1 ratio. post aspiration immediate timi flow will be observed and all the patients will be observed for adverse outcomes (mace) and complications including slow flow/no-reflow. follow-up intervals will be at the end of one month of randomization and end of 6 month of randomization.

Eligibility criteria:
inclusion criteria: * patients presenting with:-symptoms of myocardial ischemia lasting for ≥30 minutes * definite ecg changes indicating stemi: st elevation of greater than 0.1 mv in two contiguous limb leads or 0.2 mv in two contiguous precordial leads * chest pain \< 12 hours duration * total occlusion (timi 0 flow) * patients undergoing primary pci * informed consent exclusion criteria: * patients with prior history of cardiac related surgery or intervention * performance of a rescue pci after thrombolysis * known existence of a disease resulting in a life expectancy of less than 6 months * killip class iii, iv
surfactant protein d levels in covid-19 infection: case-control study

Conditions: Covid19; Pneumonia; Surfactant Protein Deficiency

Summary: this study aims to provide some insight into the variation of sd-d protein levels in patients with covid-19 (-) pneumonia, covid-19 (+) pneumonia, and ct negative covid-19 infection in comparison to the normal population through a larger number of cases. objective of the study is to determine the serum surfactant protein d (sp-d) levels in covid-19 pneumonia infection.

this study aims to provide some insight into the variation of sd-d protein levels in patients with covid-19 (-) pneumonia, covid-19 (+) pneumonia, and ct negative covid-19 infection in comparison to the normal population through a larger number of cases. subjects will assessed in accordance with the inclusion and exclusion criteria, they were divided into four groups as the ct (-), pcr (+) sars-cov-2 infection group, sars-cov-2 (+) pneumonia group, ct (+), pcr (-) suspected pneumonia group and healthy group (control group). demographic data, medical history, vital findings (fever, blood pressure, spo2), laboratory findings (complete blood count; c-reactive protein (crp), d-dimer, ferritin and hstnt parameters) and radiological findings, time to onset of symptoms, comorbid diseases, hospitalization location of the patients (service or icu), clinical scores, ct severity scores will determine. sp-d level will analyze by the enzyme-linked immunosorbent assay (elisa) method.

Eligibility criteria:
for patients; inclusion criteria: * who presented to the covid-19 outpatient polyclinic of the ed with pneumonia symptoms, * whose ct imaging's were compatible with covid-19 pneumonia in accordance with the rsnaec criteria and whose pcr tests were positive, * whose sars-cov-2 pcr tests were positive as a result of contact tracing, * who presented to the ed for further examination. * who gave their written consent to participate in the study. * giving written consent to participate in the study. exclusion criteria: * diagnosis of kidney or liver failure * acute pulmonary embolism * chronic inflammatory disease history (rheumatological disease, autoimmune disease), * pregnancy * presence of any cancer diagnosis * chronic obstructive pulmonary disease * asthma disease, * history of cerebrovascular disease. * the patients whose ct imagings were compatible with covid-19 pneumonia but whose pcr tests were negative were also excluded from the study. for control group inclusion criteria * no known acute, subacute or chronic disease history * not suffer from any infection in the last fortnight, * not to be on a particular medication, * presenting to the ed with reasons other than infectious complaints * giving written consent to participate in the study. exclusion criteria: * diagnosis of kidney or liver failure * acute pulmonary embolism * chronic inflammatory disease history (rheumatological disease, autoimmune disease), * pregnancy * presence of any cancer diagnosis * chronic obstructive pulmonary disease * asthma disease, * history of cerebrovascular disease.

Keywords: serum surfactant protein d sars-cov-2 infection pneumonia
effect of baclofen treatment on nocturnal muscle cramps in patients with lumbar spinal stenosis: a randomized clinical trial

Conditions: Lumbar Spinal Stenosis With Nocturnal Calf Cramps

Summary: nocturnal calf cramps is a common complaint in patients with lumbar spinal stenosis. the purpose of this study is to evaluate the effect of baclofen in lumbar spinal stenosis patients receiving conservative therapy. we will compare pain score, insomnia severity, functional ability and patient satisfaction between control (conservative management for spinal stenosis) and baclofen group (conservative management for spinal stenosis plus baclofen treatment).


Eligibility criteria:
inclusion criteria: 1. diagnosed lumbar spinal stenosis with mri finding 2. nocturnal calf cramps symptoms at least once per week exclusion criteria: 1. electrolyte disorder 2. congenital muscle disease 3. muscle cramps related medication (statins, diuretics, calcium channel blockers, anticonvulsants etc.) 4. cognitive impairments

Keywords: baclofen spinal stenosis nocturnal calf cramps
working memory training in adults with substance abuse and executive function deficits.

Conditions: Substance Abuse; Executive Dysfunction; Anxiety; Depression; Antisocial Personality; Reading Disabilities

Summary: the purpose of this study is to evaluate the effects of a computerized working memory training program on substance abuse, psychosocial functioning, cognitive performance and psychiatric problems in adults with substance abuse and attention problems.

the primary aim of this study is to examine the effects of 5 weeks of computerized working memory training on substance abuse. secondary aims are to explore whether effects are mediated by changes in executive functions and/or moderated by personality. also, effects on measures of psychosocial functioning, depression, anxiety and attention will be explored. follow-up assessment will be conducted at 6 months post training.

Eligibility criteria:
inclusion criteria: * treatment seeking adults with substance abuse and executive function deficits. exclusion criteria: * acute intoxication or abstinence symptoms of any substance. * psychosis.
functional recovery after partial hip arthroplasty: anterior or posterolateral approach?

Conditions: Hip Arthroplasty; Femoral Neck Fractures

Summary: hueter anterior approach as described by siguier allows an anatomical approach without muscle or tendon sections. it minimizes the rate of dislocation after primary total hip arthroplasty (1.5%, sariali)and seems to allow quicker rehabilitation. the investigators hypothesis was hueter anterior approach allows quicker functional recovery after partial hip replacement.


Eligibility criteria:
inclusion criteria: * femoral neck fracture * partial hip arthroplasty exclusion criteria: * total hip arthroplasty * osteosynthesis * pathologic fracture

Keywords: partial hip arthroplasty
does implant design improve postoperative flexion?

Conditions: Non-inflammatory Arthritis

Summary: this study will evaluate whether design features of one implant design allows more knee bend than the other. patients will have 1 design in the left knee and 1 design in their right knee. both knee surgeries will be on the same day.

the primary objective of this study is to determine whether the passive, non-weight-bearing flexion is superior with the posterior-stabilized pfc® sigma™ rp-f compared to the posterior-stabilized pfc® sigma™ rp in bilateral subjects receiving both implants and if this difference is a function of implant design.

Eligibility criteria:
inclusion criteria: * non-inflammatory arthritis * age = 40-70 years * male or female * suitable for devices in study * needing primary simultaneous bilateral knee replacements * willing to consent and authorize release of personal health information * subjects who are able to understand this clinical investigation, co-operate with investigational procedures and are willing to return to the clinic, hospital and predefined physical therapy centers for all the required postoperative follow-ups, exclusion criteria: * existing conditions that would compromise participation * multiple joint involvement * pregnant/lactating women * inflammatory arthritis * fixed flexion contracture greater than 20 degrees * previous knee replacement of any type * needing device(s) not specified in protocol * the subject is a known drug or alcohol abuser or has a psychological disorder that would compromise follow-up * those who have participated in an investigation in the last 3 months * those involved in personal injury litigation, medical-legal or workers compensation claims * failure to follow surgical technique details specified in the protocol

Keywords: total knee replacement flexion range of motion activities of daily living implant design subject satisfaction non-inflammatory arthritis
worm study: modifier genes in sudden cardiac death

Conditions: Brugada Syndrome; Long QT Syndrome 3

Summary: quest for modifier genes associated with ventricular arrhythmias in presence of a cardiac sodium channel gene (scn5a-delphe1617) mutation.

in a large dutch scn5a founder population with malignant ventricular arrhythmias, the investigators aim to identify genetic modifiers by means of whole-exome sequencing and to establish a comprehensive genotype-phenotype correlation, focussing on clinical and cellular electrophysiological characteristics and neurocardiac modulation.

Eligibility criteria:
inclusion criteria (mutation carrier group): * age ≥ 18 years. * heterozygous or homozygous carriership of scn5a-delphe1617. * confirmed kinship to the founder population by haplotype analysis using predefined microsatellite markers. * written informed consent. inclusion criteria (non-mutation carrier group): * age ≥ 18 years. * non scn5a-delphe1617 genotype. * confirmed kinship to the founder group by haplotype analysis using predefined microsatellite marker. * written informed consent. inclusion criteria spouse group * age ≥ 18 years. * biological parent of scn5a-delphe1617 positive subject participating to the worm study, and not belonging to study group 1 or 2. * written informed consent. exclusion criteria: * age ≥ 18 years. * biological parent of scn5a-delphe1617 positive subject participating to the worm study, and not belonging to study group 1 or 2. * written informed consent.
effect of vitamin d3 supplementation on symptomatic uterine fibroid in women with vitamin d deficiency

Conditions: Symptomatic Uterine Fibroid

Summary: 39 women with symptomatic uterine fibroid with serum vitamin d deficiency will receive vitamin d3 supplementation for 6 month.then symptoms and size of fibroid will be re evaluated..

effects of vitamin d supplimentation on symptomatic uterine fibroid will be checked

Eligibility criteria:
inclusion criteria: .women aged between 18-50 not currently pregnant, lactating, or planning to conceive during the study period. * women with a confirmed diagnosis of uterine fibroids (leiomyoma) through ultrasound. * serum 25-hydroxyvitamin d \[25(oh)d\] levels below 20 ng/ml (indicating vitamin d deficiency). * presence of symptoms associated with uterine fibroid, such as menorrhagia (heavy menstrual bleeding), or bulk-related symptoms (e.g., urinary frequency). * participants should be generally healthy, with no history of other chronic illnesses that could affect the study's outcomes (e.g., autoimmune diseases, cancers, severe liver or kidney diseases). * willingness to provide written informed consent for participation in the study. * no current use of hormonal therapy, other vitamin d supplements, or medications known to influence calcium metabolism or uterine fibroid growth (e.g., gnrh agonists, anti-estrogens). * participants must be willing and able to adhere to the study protocol, including attending follow-up visits and completing any required assessments or tests. exclusion criteria: * women younger than 18 or older than 50 years. * serum 25-hydroxyvitamin d \[25(oh)d\] levels of 20 ng/ml or higher. * women without a confirmed diagnosis of uterine fibroids (leiomyoma) through imaging. * pregnant or breastfeeding women, or those planning to conceive during the study period. * presence of chronic illnesses such as autoimmune diseases, cancers, or severe liver or kidney disease that could interfere with the study's outcomes. * current or recent use of hormonal therapy, other vitamin d supplements, or medications that affect calcium metabolism or uterine fibroid growth (e.g., gnrh agonists, anti-estrogens). * women who have undergone surgical interventions (e.g., myomectomy, hysterectomy) or other medical treatments specifically for uterine fibroid within the past 6 months. * women with conditions like hyperparathyroidism or calcium disorders that might affect vitamin d metabolism or fibroid growth.
congestive heart failure surgical treatmment with autologous stem cell therapy

Conditions: Congestive Heart Failure

Summary: this research study was designed to test the safety and effectiveness of autologous stem cell graft in the myocardium of patients with refractory congestive heart failure (chf) with ischemic etiology. cellular implantation will take place during off-pump revascularization surgery or during an ad hoc procedure using a mini-thoracotomy access.

primary target: determine the safety of introducing cd 34+ autologous progenitor cells (centrally grafted or mobilized in peripheral blood) in the myocardium of ischemic cardiac disease patients. secondary target: determine clinical effects of grafted cells on remodeling pathology.

Eligibility criteria:
inclusion criteria * age \>18 y/o * chf with ef \> 35% * bilirubinemia, serum transaminase\> 2.5 times normal max level * creatininemia \> 2.5 times max level * nyha class \> 3 * negative pregnancy test (for women in fertile age) exclusion criteria * impossibility to harvest the bone marrow * pregnancy or breast-feeding * history of malignant neoplasia in the 5-year period before the study (save for in-situ carcinoma of the cervix treated successfully and skin tumors - not melanomas) * incapability or unwillingness to comply with the envisaged treatment protocol, follow-up, or tests.
evaluating the effectiveness of a digital therapeutic (reviga) for people with stress or burnout

Conditions: Stress; Burnout

Summary: in this single-blinded randomized controlled clinical trial 290 patients with stress or burnout will be investigated regarding the effectiveness of a digital therapeutic for improvement of stress level, the unguided online intervention reviga. inclusion criteria are: age 18-65 years, icd-10 diagnosis z73, operationalized as above average general stress level (pss score \> 21) and increased levels of work-related stress / burnout (olbi score ≥ 2.18), living in germany, working a minimum of 20h per week, having a stable treatment for at least 30 days at the time of inclusion, and consent to participation. exclusion criterion is having plans to change the treatment in the upcoming three months at the time of inclusion. patients will be randomized and allocated to either an intervention group, receiving reviga in addition to treatment as usual (tau), or a control group, receiving only tau. the control group will be granted access to the program at the end of the study. primary endpoint will be the perceived stress measured by the pss score, with three months post-allocation being the primary time point for assessment of effectiveness. six months post allocation will be used as a timepoint for follow-up assessment of endpoints. secondary endpoints will be anxiety symptoms, level of functioning, burnout symptoms, health-related quality of life, and sick days.


Eligibility criteria:
inclusion criteria: * age 18-65 years * living in germany * employed (minimum of 20h/week) * icd-10 diagnosis z73, operationalized as above average general stress level (pss score \> 21) and increased levels of work-related stress / burnout (olbi score ≥ 2.18) * stable treatment (psychotherapy, medication, no treatment) for at least 30 days at the time of inclusion * consent to participation exclusion criteria: * plans to change treatment (psychotherapy, medication, ...) in the upcoming three months at the time of inclusion
environmental intervention for weight gain prevention

Conditions: Obesity

Summary: the primary aim of this research is to evaluate the efficacy of a multicomponent worksite-based, environmental intervention in reducing weight increase and obesity over time in working adults.

this study is a randomized trial designed to evaluate the effectiveness of a multi-component worksite intervention with strong environmental components to prevent weight gain. six worksites will be randomized to either an intervention or a no-treatment control group. the intervention will be comprised of 1) changing the availability, portion sizes, and prices of foods and beverages sold to employees in their worksites in ways that encourage healthier food choices; 2) increasing the availability of physical activity opportunities at the worksite by implementing walking programs and increasing stairwell access and attractiveness; 3) placing scales in the work environment to encourage body weight monitoring and to enable workers to set goals for their weight; and 4) to provide educational materials to all employees to make them aware of the environmental intervention and of behavioral practices likely to be effective in preventing weight gain. the intervention will be implemented for a 2-year period in each intervention site. effectiveness will be evaluated by assessing body weight, eating behavior and physical activity in a cohort of employees in both control and intervention sites at baseline and again 2 years later. weight trends in these populations will also be compared to data from national and state-level annual surveys of weight in representative population samples. data will be collected on the effects of specific intervention components via aggregate measures of food choice and physical activity.

Eligibility criteria:
inclusion criteria: * age 18 or older * generally in good health * part- or full-time employee in one of the participating worksites exclusion criteria: * work on site \<50% of the time * work second or third shift

Keywords: obesity obesity prevention worksite environment intervention
mifepristone-misoprostol vs. misoprostol alone for second trimester fetal death

Conditions: Fetal Death

Summary: the primary aim of this trial is to compare the efficacy of mifepristone-misoprostol versus misoprostol alone for treatment of intrauterine fetal demise between 14 and 28 weeks lmp.

the primary aim of this trial is to compare the efficacy of mifepristone-misoprostol versus misoprostol alone for treatment of intrauterine fetal demise between 14 and 28 weeks lmp. this will be a randomized controlled double-blinded trial of 150 women comparing misoprostol alone to mifepristone plus misoprostol for evacuation of the uterus after fetal demise in the second and third trimester. all women in the trial will undergo routine screening and pre-medical induction care per standard practice at the hospital. all eligible women agreeing to participate in the study will be randomized to receive one of the following regimens: 1. study group one: 200mg mifepristone followed in 24 hours by repeated doses of 200mcg buccal misoprostol given every 3 hours; 2. study group two: placebo followed in 24 hours by 200mcg buccal misoprostol given every three hours.

Eligibility criteria:
inclusion criteria: * demised fetus of between 14 to 28 weeks duration confirmed by ultrasound * have no contraindications to study procedure, according to provider * be able to consent to procedure, either by reading consent document or by having consent document read to her * be willing to follow study procedures. exclusion criteria: * allergies or other contraindications to the use of mifepristone or misoprostol; * placental abruption with active hemorrhage, * complete placenta previa, extreme uterine structural anomalies, or other contradictions to vaginal delivery of the fetus; * presentation in active labor (moderate to severe contractions every 10 minutes or less); * transmural uterine scars; * four or more previous deliveries.

Keywords: fetal death mifepristone misoprostol
epidemiology of respiratory virus infections in children

Conditions: Respiratory Virus Infection

Summary: this study aims to prospectively estimate the incidence of respiratory virus (rv) infections in children with symptoms of an upper respiratory tract infection (urti) or lower respiratory tract infection (lrti) at st. jude children's research hospital (sjcrh) using the filmarraytm system, a novel highly sensitive and rapid assay for rv detection. an aliquot from the leftover sample remaining after clinical diagnostic testing will be used for filmarraytm analysis. patients will be accrued on the study over a one year period.

the primary objective of the study is: * prospectively estimate the incidence of respiratory virus (rv) infections in children with symptoms of an upper respiratory tract infection (urti) or lower respiratory tract infection (lrti) at st. jude children's research hospital(sjcrh). the secondary objectives of the study are: * study the association between rv infections and clinical variables. * prospectively estimate the duration of rv infections in symptomatic children at sjcrh. * compare the sensitivity and specificity of the current molecular method of analysis of respiratory viruses with the filmarraytm method.

Eligibility criteria:
inclusion criteria: * birth to less than or equal to 18 years. * patients with an urti or lrti undergoing collection of respiratory secretions at sjcrh, by nasopharyngeal wash, nasopharyngeal swab, tracheal aspirate or bronchoalveolar lavage as ordered by the treating physician.

Keywords: upper respiratory tract infection lower respiratory tract infection